Document is current
Any future updates will be listed below
-
Authors
Choquet, Sylvain
Marchal, Clarisse
Deygas, Floriane
Deslandes, Marine
Macher, Nahid
de Pouvourville, Gérard
Levy, Vincent
-
Funding
Funding for this research was provided by:
Janssen Cilag France
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 18 June 2024
First Online: 5 July 2024
Declarations
:
: This study was approved by the French National Institute for Health Data (approval No 202441 on November 15 2018 and No 1491132 on April 2 2020). It was conducted using anonymized data, approved by the French Data Protection Authority (CNIL, approval No 918407 on December 21 2018 and No 918407V1 on June 26 2020). Written informed consent was not required for participation in this study, in accordance with national legislation and institutional requirements.
: SC reports personal fees from Gilead-Kite, Novartis, Roche, Abbvie, Sandoz, Sanofi, Janssen, Celgene-BMS, Takeda, Atara, Astra Zeneca, Pierre Fabre, Viatris. CM and FD are full time employees of PELyon. MD is full time employees of Janssen Cilag. NM was employed by Janssen Cilag when this study was performed. GdP reports personal fees from UCB, Janssen, Abbott, Alexion, Novartis, MSD, BMS, Astra Zeneca, Astellas, Moderna, Boehringer Ingelheim, EFPIA. VL reports personal fees from Janssen, Astra Zeneca, CSL Behring, BeiGene.
